AMPH NASDAQ
Amphastar Pharmaceuticals, Inc.
1W: +5.0%
1M: -13.5%
3M: -36.4%
YTD: -31.4%
1Y: -27.6%
3Y: -57.7%
5Y: -9.1%
$18.41
+0.25 (+1.38%)
Weekly Expected Move ±12.5%
$13
$15
$17
$19
$21
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (39)
Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19
12 Health Care Stocks Moving In Friday's Intraday Session
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday
12 Health Care Stocks Moving In Friday's Pre-Market Session
Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Amphastar (AMPH) Q1 2026 Earnings Transcript
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Here are the major earnings after the close Thursday
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Boston Trust Walden Corp Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $29.50 Consensus Target Price from Brokerages
SG Americas Securities LLC Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH
Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $29.50 Consensus Price Target from Brokerages
Generic drug suppliers could face pressure from Strait of Hormuz closure
Algert Global LLC Acquires 268,612 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 12-Month Low – Here’s Why
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Down Following Analyst Downgrade
Flutter Entertainment Posts Downbeat Q4 Results, Joins Zscaler, Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session (CORRECTED)
Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product
Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025
Here are the major earnings after the close Thursday
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives $31.00 Consensus Price Target from Analysts
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
Amphastar Director Sells 16,679 Shares for $441,800
Amphastar Announces FDA Approval for Teriparatide Injection
Capital Fund Management S.A. Takes $931,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference